Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank all co-workers at the MLL Munich Leukemia Laboratory for approaching together many aspects in the field of leukemia diagnostics and research by their dedicated work, as well as all physicians for providing samples and caring for patients as well as collecting data.

Disclosure statement

CH, WK, and TH declare part ownership of Munich Leukemia Laboratory (MLL). IS, AS, and MM are employed by the MLL Munich Leukemia Laboratory.